|
gptkbp:instanceOf
|
gptkb:drug
chemotherapy medication
|
|
gptkbp:activeIngredient
|
paclitaxel
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01CD01
|
|
gptkbp:brand
|
gptkb:Abraxane
|
|
gptkbp:CASNumber
|
33069-62-4
|
|
gptkbp:category
|
antineoplastic agent
mitotic inhibitor
taxane
|
|
gptkbp:contraindication
|
hypersensitivity to paclitaxel
severe neutropenia
|
|
gptkbp:eliminatedIn
|
hepatic
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:form
|
gptkb:albumin-bound_paclitaxel
|
|
gptkbp:genericName
|
gptkb:albumin-bound_paclitaxel
|
|
gptkbp:halfLife
|
27 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abraxane
|
|
gptkbp:indication
|
metastatic non-small cell lung cancer
metastatic breast cancer
locally advanced breast cancer
metastatic pancreatic cancer
|
|
gptkbp:KEGGID
|
D05367
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Celgene
|
|
gptkbp:mechanismOfAction
|
microtubule inhibitor
|
|
gptkbp:medlinePlus
|
a607070
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
89-98%
|
|
gptkbp:PubChem_CID
|
36314
CHEMBL325635
DB01229
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
alopecia
peripheral neuropathy
neutropenia
|
|
gptkbp:UNII
|
P88XT4IS4D
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:cancer
pancreatic cancer
|
|
gptkbp:bfsParent
|
gptkb:Abraxis_BioScience
gptkb:Celgene
gptkb:Bristol_Myers_Squibb
|
|
gptkbp:bfsLayer
|
6
|